| CAS: | 15450-76-7 | |||
| 分子式: | C9H7NO2 | |||
| 分子量: | 161.16 | |||
| 熔点: | ~290 °C | |||
| 中文名称: |
| |||
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Q822160 | MACKLIN | 2,8-喹啉二醇 | 97% | 28元/1g; 44元/5g; 169元/25g; 675元/100g; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||
储存:室温 状态:浅棕色粉末 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| D3819 | TCI | 2,8-Dihydroxyquinoline | >98.0%(GC)(T) | 190元/5G; 690元/25G; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
技术规格
物性(参考值)
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Y10292 | Alfa Aesar | 8-Hydroxy-2(1H)-quinolinone | 158元/5g; 272元/10g; 548元/25g; 1966元/100g; 8223元/500g; | 展开 | |||||||||||||||||||||||||||||||||||||||||||||||||
基本信息 分子量 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 37640 | Sigma-Aldrich | 2,8-Quinolinediol | ≥99.0% (HPLC) | 380.09元/1 G; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 2,8-Quinolinediol is a quinolone derivative. It has been reported as metabolite of 8-hydroxyquinoline-N-oxide in rabbits. Synthesis of 2,8-quinolinediol has been reported. It is reported as one of the six possible forms of 8-hydroxycarbostyril. It has been detected as new UV-absorbing compound (UAC) in cow milk and its structure was elucidated using HRMS and by 1H, 13C and 1H ×13C NMR.It is also known as 8-hydroxycarbostyril or 8-hydroxyquinolin-2(1H)-one. 应用 2,8-Quinolinediol is suitable for use as standard in a study to identify the urinary metabolites for the toxicity related processes and pathogenesis induced by doxorubicin (DOX) to rats by online and off-line LC-MS techniques. It may be used as starting reagent for the preparation of two powerful β2-adrenergic receptor agonists, used for the treatment of asthma:
包装 1, 5 g in glass bottle 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 040217 | Fluorochem | Quinoline-2,8-diol | 97% | 220元/1g; 308元/5g; 528元/10g; 1034元/25g; 3058元/100g; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||